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Summary 
In multiple sclerosis (MS) T cells aberrantly recognise self-peptides of the 
myelin sheath and attack the central nervous system (CNS). Antigen-specific 
peptide immunotherapy, which aims to restore tolerance while avoiding the use 
of non-specific immunosuppressive drugs, is a promising approach to combat 
autoimmune disease, but the cellular mechanisms behind successful therapy 
remain poorly understood. Myeloid-derived suppressor cells (MDSCs) have 
been studied intensively in the field of cancer and to a lesser extent in 
autoimmunity. Because of their suppressive effect on the immune system in 
cancer, we hypothesised that the development of MDSCs and their interaction 
with CD4+ T cells could be beneficial for antigen-specific immunotherapy. Thus, 
changes in the quantity, phenotype and function of MDSCs during tolerance 
induction in our model of MS were evaluated. We reveal, for the first time, an 
involvement of a subset of MDSCs, known as polymorphonuclear (PMN)-
MDSCs, in the process of tolerance induction. PMN-MDSCs were shown to 
adopt a more suppressive phenotype during peptide immunotherapy and inhibit 
CD4+ T cell proliferation in a cell contact-dependent manner, mediated by 
arginase-1. Moreover, increased numbers of tolerogenic PMN-MDSCs, such as 
observed over the course of peptide immunotherapy, were demonstrated to 
provide protection from disease in a model of experimental autoimmune 
encephalomyelitis (EAE).  
  
Introduction 
Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous 
system where immune cells attack myelinated axons of the brain and spinal 
cord (1). The ideal treatment of MS would be to specifically target the disease-
causing immune cells without compromising the broader function of the immune 
system. A promising approach to the treatment of MS relies on the use of 
soluble, synthetic peptides, based on the sequence of known disease-
associated antigens, to promote tolerance induction. In the Tg4 model of 
experimental autoimmune encephalomyelitis (EAE), T cells express a 
transgenic TCR specific for the immunodominant epitope of Myelin Basic 
Protein, MBPAc1-9 (2). The development of induced EAE in this model can be 
prevented by repetitive administration of the cognate peptide (3). This is 
characterised by the induction of anergy in CD4+ T cells and a switch in serum 
cytokines from a dominant IFN- response towards IL-10. A dose escalation 
protocol for subcutaneous delivery of the high self-antigen doses, required for 
effective tolerance induction, was shown to be highly effective and safe (4, 5). 
Escalating dose immunotherapy (EDI) leads to an upregulation of co-inhibitory 
molecules including LAG-3, TIGIT, TIM-3 and PD1 on CD4+ T cells (5). Another 
study previously found that expression of TIM-3 on T cells resulted in the 
increase in a population of CD11b+ Ly6G+ cells (6). These innate cells, known 
as myeloid-derived suppressor cells (MDSCs), were first described more than 
30 years ago in cancer patients (7). Since then, their detrimental role in cancer 
has been well characterised. These immature myeloid cells accumulate in 
tumours and contribute highly to immune escape by suppressing antigen-
specific T cell responses (8, 9). Only more recently has a potential beneficial 
role for MDSCs in autoimmune diseases, including Type-1 diabetes (10) and 
EAE (11) become appreciated, demonstrating that MDSCs can limit T cell-
mediated pathology and tissue injury. In mice, MDSCs are broadly defined as 
CD11b+ Gr1+ cells. Anti-Gr1 antibodies recognise two targets, LY6G and LY6C. 
A further distinction in MDSC subsets can be made based on their differential 
LY6G and LY6C expression (12). Polymorphonuclear MDSCs (PMN-MDSCs) 
have a CD11b+ LY6G+ LY6Clow phenotype, whereas MDSCs with monocytic 
morphology (M-MDSCs) are CD11b+ LY6G– LY6Chi (13). MDSCs use multiple 
mechanisms to suppress T cell proliferation. The majority of studies have found 
an involvement of the enzymes arginase-1 and iNOS in MDSC-mediated 
suppression of T cells (14, 15). More recently, other mechanisms of 
suppression deployed by MDSCs have been revealed, including the production 
of the enzyme indoleamine 2,3-dioxygenase (IDO) and IL-10 (16, 17). In 
addition to these soluble factors, cell surface molecules, including PD-L1, 
Galectin-9, CD40 and CD80, have been suggested to play a role in the 
suppression of T cells,  (6, 18-20). Here, we reveal for the first time a previously 
unknown role for PMN-MDSCs in antigen-specific tolerance induction.  
  
Materials and Methods 
Mice 
All animal experiments were carried out under a UK Home Office Project 
Licence and approved by the University of Bristol ethical review committee. 
Mice were bred and kept under specific pathogen-free conditions. 
The Tg4 T cell receptor (TCR)-transgenic mouse was described previously (21). 
CD4+ T cells in this model express a V4 V8.2 transgenic TCR specific for the 
acetylated nine-residue peptide of MBP (Ac1-9) in the context of I-Au.  
Peptides 
MBPAc1-9(4K) (Ac-ASQKRPSQR) and the high affinity analogue MBPAc1-9(4Y) 
(Ac-ASQYRPSQR) were custom-synthesized by GL Biochem Shanghai. 
Escalating-dose peptide immunotherapy 
For tolerance induction, mice were treated subcutaneous (s.c.) every 3–4 days 
with a total of 6 doses of MBPAc1-9(4Y) in PBS in increasing doses: 0.08g, 
0.8g, 8g, 3 x 80g. 
Flow cytometry analysis 
The following anti-mouse antibodies (Biolegend unless stated otherwise) were 
used: CD4 A700, IL-17A PerCP-Cy5.5 (eBioscience), IFN- APC (eBioscience), 
Foxp3 PE (eBioscience), Ly6G A700, Ly6C APC-Cy7, CD11b PerCP-Cy5.5, 
Galectin-9 PE, CD80 BV421, CD86 BV605, CD40 PE-Cy7, PD-L1 APC, MHCII 
APC-Cy7. Fixable viability dye-eFluor780 (eBioscience) was used to exclude 
dead cells. Samples for intracellular staining were activated with 5 ng/ml PMA 
(Sigma) plus 500ng/ml Ionomycin (Sigma) and Golgi Stop (BD Bioscience) for 
three hours. Cell proliferation dye-ef450 (CPD-ef450, eBioscience) was used to 
visualize cell divisions or calculate division and proliferation indexes. FACS 
acquisition was performed on an LSR-II flow cytometer (Becton-Dickinson) and 
results were analysed using FlowJo software (TreeStar Inc). 
Magnetic cell isolation 
Naïve CD4+ T cells were isolated using the MagniSort™ Mouse CD4 Naïve T 
cell Enrichment Kit (#8804-6824-74) from eBioscience according to the 
instructions. Mouse CD11c+ dendritic cells (DCs) from the spleen were isolated 
using the CD11c Microbeads Kit from MACS Miltenyi (#130-052-001). 
3[H]-Thymidine proliferation assay 
For some 3[H]-thymidine proliferation assays, 1x106 splenocytes or 2x105 lymph 
node cells were cultured, in triplicate, with titrated doses of MBPAc1-9(4K) in a 
96-well round bottom plate. For other experiments, CD4+ T cells were 
magnetically isolated from the spleen and a 3[H]-Thymidine assay was set up 
with titrated doses of MBPAc1-9(4K) and irradiated APCs. Cells were cultured for 
three days at 37°C in a CO2 incubator and 0.5 Ci of 3[H]-Thymidine was added 
to wells for 16 h before measurement using a 1450 Micro- counter (Wallac). 
In vitro suppression assay 
PMN-MDSC and antigen-experienced CD4+ T cells (Tag) from MBPAc1-9(4Y)-
treated mice were FACS sorted. PMN-MDSCs and CD4+ T cells were either co-
cultured at a ratio of 1:3 together with CD11c+ cells as antigen-presenting cell 
(APC) in a APC:T cell ratio of 1:10 and MBPAc1-9(4K)-peptide (10g/ml) or at a 
1:1 ratio in the presence of 1 g/ml plate-bound anti-CD3 and 2 g/ml anti-
CD28 (both from BioXCell). Both CD4+ T cell populations were labelled with cell 
proliferation dye eFluor®450 before co-culture. 1x106 CD4+ T cells were used 
for the co-culture for four days in a 48-well plate or 1x105 T cells in a 96-well 
plate. Some experiments were performed in the presence of neutralising 
antibodies against: PD-L1, Galectin-9, CD40, CD80, CD86 (all from Biolegend) 
and IL-10R (BioXCell). For experiments regarding the effect of iNOS and 
arginase-1, 0.5 mM L-NMMA (Merck) or 0.5 mM BEC (Santa Cruz 
Biotechnology) respectively were added at the beginning of the culture. To 
investigate if the suppressive effect of PMN-MDSC is contact dependent, PMN-
MDSC and CD4+ T cells were separated during the co-culture using a transwell 
assay (Corning). 
Induction and evaluation of EAE 
EAE was induced by adoptive transfer of MBPAc1-9-specific Th1 cells. Briefly, 
Tg4 splenocytes were cultured for 5 days with 10 g/ml MBPAc1-9(4K) and 
5 ng/ml rmIL-12 (PeproTech), in the presence or absence of PMN-MDSCs from 
tolerised Tg4 mice at a ratio of 1:3. 20 U/ml rhIL-2 (R&D Systems) was added 
after 72 h. In vitro-polarized Th1 cells (5×106) were transferred into Tg4 animals. 
EAE was assessed twice daily with the following scoring system: 0, no signs; 1, 
flaccid tail; 2; impaired righting reflex and/or gait; 3, hind limb paralysis; 4, 
forelimb and hind limb paralysis; 5, moribund. 
Results 
Increase in M-MDSCs and PMN-MDSCs during EDI 
Two subpopulations of MDSCs are currently defined in mice; monocytic MDSCs 
(M-MDSCs) characterised by a CD11b+ Ly6G- Ly6Chigh phenotype and 
polymorphonuclear MDSCs (PMN-MDSCs) that have a CD11b+ Ly6G+ Ly6Clow 
phenotype. We observed that after a course of EDI with MBPAc1-9(4Y) the 
percentage of MDSCs among CD11b+ cells had increased systemically 
compared to control-treated animals (Figure 1A). In the spleen, inguinal lymph 
nodes (ILN), brachial lymph nodes (BLN), liver, lung, brain and spinal cord, the 
increase in the percentage of PMN-MDSCs was more pronounced than that of 
M-MDSCs. The lung was the only organ where we observed an increase in the 
frequency of both MDSC subsets. Considering these results, we decided to 
concentrate on PMN-MDSCs for further experiments in which we assessed 
kinetics of MDSC changes during EDI. Expressed as a percentage of all 
leukocytes, the frequency of PMN-MDSCs peaked after the 3rd treatment in 
most organs other than the liver, where a significant increase was not 
established until the 5th treatment (Figure 1B). These experiments did not detect 
a statistically significant difference in the frequency of PMN-MDSCs in the 
spinal cord. In addition to the frequency of PMN-MDSCs, we also assessed 
absolute cell numbers for each organ (Figure 1C). These revealed a very similar 
pattern to the changes in the percentages.  
 
 
Dose escalation immunotherapy alters PMN-MDSC phenotype 
The pronounced accumulation of PMN-MDSCs after the 3rd dose of peptide 
treatment led us to further investigate PMN-MDSC phenotype and function at 
this point. At this time, CD4+ T cells also start to undergo phenotypic changes 
that characterise the EDI protocol, namely the reduction in effector cytokines 
and the switch to IL-10-production in CD4+ T cells (5). To further characterise 
the phenotype of PMN-MDSCs and find ways in which they might influence the 
function of CD4+ T cells during the course of EDI, we investigated several 
markers that can affect CD4+ T cell activation, including Galectin-9, PD-L1, 
CD40, CD80 and CD86. Representative staining of splenic PMN-MDSCs is 
shown in Figure 2A. The extent to which expression of these markers on PMN-
MDSCs was altered by EDI varied greatly depending on the location of the 
cells. For example, Galectin-9, PD-L1 and CD86 expression was increased on 
splenic PMN-MDSC compared to mice receiving PBS only as a control (Figure 
2B). In other organs, such as the lung, Galectin-9 was increased but PD-L1 
decreased in comparison to control-treated animals. There was no difference in 
CD40 expression in any of the organs evaluated. CD80 expression on PMN-
MDSCs trended towards a reduction in MBPAc1-9(4Y)-treated animals but this 
was significant only in the ILNs.  
Splenic PMN-MDSC suppress antigen-mediated proliferation of naïve 
CD4+ T cells in vitro 
In order to establish whether the PMN-MDSCs that developed during EDI do 
indeed have immune regulatory properties, we first assessed their effect on 
CD4+ T cell proliferation in vitro. Naïve Tg4 CD4+ T cells (Tnaiv) and antigen-
experienced CD4+ T cells (Tag) labelled with cell proliferation dye were co-
cultured with CD11c+ APCs and 10 g/ml of cognate peptide, in the presence or 
absence of PMN-MDSCs from tolerised mice. After the four-day co-culture we 
measured CD4+ T cell proliferation by flow cytometry and calculated the 
proliferation and division indexes. These experiments revealed that addition of 
PMN-MDSCs to the T cell cultures reduced the division index of proliferating 
naïve CD4+ T cell, but to our surprise, PMN-MDSCs were unable to reduce the 
proliferation of CD4+ Tag cells (Figure 3A). Importantly, addition of PMN-
MDSCs led to the expansion of CD4+ Foxp3+ regulatory T cells within the CD4+ 
T cell population, although this only reached statistical significance for the 
combined data from 5 separate co-cultures with CD4+ Tag cells (Figure 3B). 
This could potentially be explained by the additional requirement of IL-2 for 
optimal CD4+ Treg cell expansion. This cytokine is secreted abundantly by 
CD4+ Tag cells but not naïve CD4+ T cells.    
Splenic PMN-MDSC suppress the proliferation of antigen-experienced 
CD4+ T cells activated by a polyclonal stimulus in vitro in a cell-contact 
dependent manner 
Next we sought to determine if, in addition to suppression of an antigen-driven 
response, PMN-MDSC in the Tg4 model could act as suppressors of CD4+ T 
cell proliferation activated in vitro without antigen or APC. Either Tnaiv or Tag 
cells, labelled with proliferation dye, were cultured together with PMN-MDSCs 
from tolerised mice at a ratio of 1:1 for four days on a plate coated with anti-
CD3 and anti-CD28. The suppressive activity of PMN-MDSCs is their main 
characteristic but to make sure that this suppressive ability is the result of 
tolerance induction through EDI, we also isolated PMN-MDSCs from PBS-
treated mice as a control and included those in our proliferation assays. PMN-
MDSCs from tolerised mice were found to be potent suppressors because they 
reduced the division index of both naïve CD4+ T cells and antigen-experienced 
T cells significantly (Figure 4A+B). On the other hand, PMN-MDSCs from 
control mice were not able to reduce the proliferation. In order to determine if 
the suppressive activity seen before is cell contact-dependent, transwell 
experiments were performed. In these experiments, CD4+ Tag cells were 
cultured on an anti-CD3+anti-CD28-coated plate, separated by a membrane 
from splenic, FACS-sorted PMN-MDSC from tolerised Tg4 mice. Physical 
separation of PMN-MDSCs and responder cells abrogated the suppressive 
effect on CD4+ T cell proliferation, which suggested that the PMN-MDSC-
mediated suppression of CD4+ T cell proliferation is cell contact-dependent 
(Figure 3C). 
PMN-MDSCs use a range of suppressive mechanisms 
Several molecules have previously been suggested to mediate cell contact-
dependent suppression by PMN-MDSCs. To investigate the molecules that may 
be involved in the suppressive effect of PMN-MDSCs, blocking antibodies 
targeting molecules expressed on the surface of PMN-MDSCs, namely 
Galectin-9, PD-L1, CD40, CD80 and CD86, or anti-IL-10R were added to the 
co-culture. The suppressive activity of PMN-MDSCs was impaired under 
several of these conditions (Figure 5A). The addition of either anti-Galectin-9 or 
PD-L1 alone did not abrogate the suppressive activity of PMN-MDSCs whereas 
the co-blockade of both ligands restored CD4+ T cell proliferation at least in 
part, indicating a synergistic effect of Galectin-9 and PD-L1 in CD4+ T cell 
suppression. The addition of blocking antibodies targeting the surface 
molecules CD40, CD80 or CD86 restored CD4+ T cell proliferation in a similar 
fashion. IL-10 receptor signalling, however, did not appear to be essential for 
the suppressive activity of PMN-MDSCs because in our in vitro suppression 
assay blockade of IL-10R (Figure 5A) did not alleviate CD4+ T cell suppression. 
In addition to these cell surface antigens, soluble factors may still be involved in 
mediating suppression of CD4+ T cells in close proximity. Therefore, the 
possible role of iNOS and arginase-1 in mediating the suppression of CD4+ T 
cell proliferation was investigated further by the addition of an inhibitor of iNOS, 
(NG-monomethyl-L-arginine (L-NMMA), or an inhibitor of arginase-1, (S-(2-
boronoethyl)-L-cysteine (BEC) to the suppression assay (Figure 5B). The 
addition of the arginase-1 inhibitor but not iNOS inhibitor abrogated the 
suppressive effect of PMN-MDSCs.  
Frequencies and phenotype of PMN-MDSCs in peripheral organs in 
diseased versus tolerised mice 
The role of MDSCs in autoimmunity remains controversial. On the one hand, 
the accumulation of CD11b+Ly6Chigh M-MDSCs in EAE positively correlated 
with disease severity and an improvement in pathology was accompanied by 
the reduction of these cells (22, 23). However, in contrast to these studies their 
beneficial role in autoimmune diseases including EAE has become increasingly 
appreciated in recent years (11). MDSCs have been shown to be able to limit T 
cell-mediated pathology and tissue injury as a result of their suppressive activity 
(24). To assess the dynamics of PMN-MDSCs during EAE in the TG4 model, 
mice were treated with MBPAc1-9(4Y) to confer protection or with PBS only as a 
control, prior to the induction of EAE. Animals were culled at the peak of 
disease when PBS-treated animals had an average disease score of 3 with 
complete hind limb paralysis (typically around day 14 post immunisation). 
MBPAc1-9(4Y)-treated animals, which displayed no EAE symptoms, were taken 
at the same time of analysis. This confirmed that the frequency of PMN-MDSCs 
was increased in animals in which EAE was induced compared to animals that 
were not primed for disease (Figure 6A compared to Figure 1B). In fact, the 
frequency of PMN-MDSC in mice with EAE was significantly higher in many of 
the organs examined than in mice that had been tolerised using EDI (Figure 
6A). This then prompted the question whether qualitative changes may be more 
important for the immunosuppressive of MDSCs than quantitative changes. We 
therefore examined if the PMN-MDSC that arise during the development of EAE 
are phenotypically different from the ones that are generated during tolerisation. 
Indeed, we observed a significant two-fold lower expression of CD40 on PMN-
MDSCs in the spinal cord of mice with EAE compared to tolerised animals 
(Figure 6B). Furthermore, we detected a significantly lower expression of CD80 
in the CNS compartment both in the brain and spinal cord, in tolerised animals 
compared to animals with EAE (Figure 6B). Finally, we found an increased 
expression of Galectin-9 and PD-L1 in both the spleen and lymph nodes in 
tolerised mice compared to control mice. However, the expression levels of 
these two markers in tolerised animals differ greatly between the spleen and 
inguinal lymph nodes in particular (Figure 6B). These findings hint at the 
possibility that phenotypic differences between the PMN-MDSCs that develop 
after EAE development or after tolerisation play a role in their functional 
dichotomy. 
Splenectomy impairs the increase in the number of PMN-MDSCs post EDI 
and prevents tolerance induction 
We demonstrated an increase in the number of splenic PMN-MDSCs, with a 
marker profile distinct from PMN-MDSCs residing in the lymph nodes. 
Therefore, we wanted to further investigate the role of the spleen in tolerance 
induction. To achieve this, we performed splenectomies or sham operations 
prior to tolerance induction in Tg4 mice and analysis of the number of PMN-
MDSCs in the lymph nodes, lung or liver. As shown in Figure 7A+B, 
splenectomy resulted in a statistically significant abrogation of the increase in 
the percentage of PMN-MDSCs after EDI only in the ILNs, although a similar 
trend was observed in the BLNs and, in particular, the liver. Furthermore, we 
found that an intact spleen was essential for successful tolerance induction with 
MBPAc1-9(4Y). Removal of the spleen did not affect disease development in 
control-treated animals (Figure 7C), whereas animals receiving MBPAc1-9(4Y)-
treatment after a sham operation were largely protected against the induction of 
EAE. Their splenectomised counterparts all developed severe EAE. In order to 
allow for statistical analysis of the EAE scores of all animals over the course of 
the experiment, the area under the curve (AUC) was calculated and this 
demonstrated the same trend (Figure 7C). 
Signalling through the IL-10 receptor controls PMN-MDSC accumulation 
and phenotype 
Our previous data showed that IL-10 receptor signalling is not essential for the 
suppressive activity of PMN-MDSCs because blockade of IL-10R signalling by 
an antibody did not alleviate CD4+ T cell suppression in vitro (Figure 5A). 
However, we were still interested to know if IL-10 signalling affects the quantity 
and phenotype of PMN-MDSCs. First, we treated Tg4IL-10-/- mice with either 
PBS or MBPAc1-9(4Y) according to the EDI protocol until the 3rd dose before 
isolating the spleen and lymph nodes to determine the quantity of PMN-MDSCs. 
The significant increase of PMN-MDSCs that results from peptide treatment in 
IL-10-sufficient animals was impaired in spleen and lymph nodes of Tg4IL-10-/- 
mice (Figure 8A+B). This was true for both the increase in the percentage and 
absolute number of PMN-MDSCs in the lymph nodes (Figure 8A+B). The fact 
that we detected fewer PMN-MDSCs in IL-10-/- animals could be either a direct 
effect because MDSCs can express IL-10R (25) or an indirect effect of excess 
CD4+ T cell activation in response to antigenic challenge in IL-10-/- mice. The 
reduction in the number of PMN-MDSCs in Tg4IL-10-/- animals led us to further 
characterise the phenotype of PMN-MDSC in this model. The reduction of 
CD80 expression commonly observed in wild-typeTg4 mice after MBPAc1-9(4Y)-
treatment is abrogated in IL-10-/- mice (only statistically significant in the ILNs) 
(Figure 8C). Moreover, the substantial increase of CD86 expression on PMN-
MDSCs from wild-type Tg4 mice in the spleen post EDI was impaired in Tg4IL-
10-/- mice (Figure 8D). 
PMN-MDSCs reduce CD4+ T cell proliferation after antigen challenge in 
vivo 
In order to test if, in addition to their inhibitory effect in vitro, PMN-MDSCs are 
able to reduce the proliferation of CD4+ T cells in vivo, Tg4 mice received a cell 
transfer of 1.5x106 FACS-sorted PMN-MDSC from tolerised mice i.p. three days 
before priming with MBPAc1-9(4K) peptide in complete Freund’s adjuvant (CFA) 
at the base of the tail. Ten days later, spleen and ILNs were harvested and a 
3[H]-Thymidine assay was set up. The proliferative response after restimulation 
in vitro with cognate peptide was significantly reduced in cells from the spleen 
but not the ILNs from mice that had received a transfer of PMN-MDSCs 
compared to mice that did not receive PMN-MDSCs (Figure 9A). Next, to 
exclude the possibility that transferred PMN-MDSCs still present in the whole 
splenocyte suspensions mediate suppression of CD4+ T cell proliferation at the 
time of restimulation in vitro, CD4+ T cells were magnetically isolated from the 
spleen and a separate 3[H]-Thymidine assay was set up with titrated doses of 
MBPAc1-9(4K) and irradiated APCs. Again, the proliferation of CD4+ T cells 
isolated from mice that had received a transfer of PMN-MDSCs was 
significantly reduced over a range of MBPAc1-9(4K) peptide concentration 
compared to cells from mice that did not receive the transfer (Figure 9B). In 
addition, intracellular cytokine staining demonstrated a small but not significant 
reduction in the production of the proinflammatory cytokines IFN- or IL-17 by 
CD4+ T cells from animals that had received a PMN-MDSC transfer, upon 
restimulation with PMA/Ionomycin (Figure 9C). 
 
PMN-MDSCs ameliorate encephalogenicity of Th1 cells. 
Given the reduction in CD4+ T cell proliferative capacity after adoptive transfer 
of PMN-MDSCs ex vivo, we asked if PMN-MDSCs would interfere with CD4+ T 
cell pathogenicity. Therefore, MBP-specific CD4+ T cells were polarised in vitro 
under normal Th1 conditions either with or without the addition of PMN-MDSCs, 
prior to adoptive transfer to Tg4 recipients to induce a passive form of EAE. The 
addition of PMN-MDSC during Th1 polarisation led to a clear amelioration of 
EAE severity and to an enhanced recovery from disease, demonstrating their 
disease-limiting propensity (Figure 10 and Table 1).  
  
Discussion 
In this study, we show for the first time that MDSCs, and PMN-MDSCs in 
particular, accumulate during the course of EDI in various organs from the CNS 
to the periphery. The preferential expansion of PMN-MDSCs over M-MDSCs 
does not come as a complete surprise because PMN-MDSCs represent the 
major pool of circulating and expanding MDSCs in both mice and humans in the 
tumour environment (26), revealing a 3:1 ratio of PMN-MDSCs to M-MDSCs 
(27). The more pronounced accumulation of PMN-MDSC after the 3rd dose of 
peptide treatment may result from the fact that Tg4 mice showed a peak in the 
amount of IL-6 and IL-17 after this dose (5). These cytokines are known to 
mediate the accumulation of MDSCs and their immunosuppressive function (28-
31). The PMN-MDSCs that we induced during antigen-specific peptide 
immunotherapy were able to reduce the proliferation of CD4+ T cells and 
expand CD4+ Foxp3+ T cells in vitro. Moreover, adoptive transfer of PMN-
MDSCs prior to priming of Tg4 mice with MBPAc1-9(4K) in CFA reduced the 
CD4+ T cell proliferative response upon restimulation ex vivo. We found that 
PMN-MDSCs were able to suppress naïve CD4+ T cell proliferation induced by 
either an antigen-specific or non-specific stimulus. Surprisingly, PMN-MDSCs 
reduced the proliferative response of antigen-experienced T cells only when 
stimulated non-specifically with anti-CD3+anti-CD28. A previous study showed 
that MDSCs from the tumour site and spleen of the same mouse can differ in 
their ability to suppress CD8+ T cell proliferation even though no phenotypic 
differences could be detected(31). Both MDSC-populations were able to 
suppress CD8+ T cell proliferation in an antigen-specific manner, however 
splenic MDSCs did not suppress CD8+ T cell proliferation in response to anti-
CD3+anti-CD28. These differences in suppression could be explained by the 
tumour environment, where suppressive factors are present that are absent in 
the spleen. But, all PMN-MDSCs we studied were isolated from the spleen and 
only the method of CD4+ T cell stimulation differed. So far, we have no definitive 
explanation as to why in our experiments antigen-experienced cells could be 
suppressed when stimulated with antibody but not when stimulated with 
antigen, but it could have to do with either the affinity of the interaction or the 
involvement of co-stimulatory or co-inhibitory molecules. It further remains to be 
determined if the fact that the antigen-experienced T cells in our experiments 
have had more than one previous antigen encounter affects their ability to be 
suppressed by MDSCs.  
Most of the published studies, as well as our own results, indicate that MDSCs 
need direct cell-cell contact to exert their immunosuppressive function, which 
suggests that they act either through cell surface receptor-ligand interactions or 
through release of soluble mediators that act only in close proximity (32). 
MDSCs have previously been shown to use multiple mechanisms to suppress T 
cell proliferation (14). The majority of studies have found an involvement of the 
enzymes arginase-1 and iNOS in MDSC-mediated suppression of T cells (14, 
15). However, the addition of an inhibitor of iNOS, NG-monomethyl-L-arginine 
(L-NMMA) did not ablate the suppressive activity of PMN-MDSCs in our hands, 
whereas the arginase-1 inhibitor (BEC) restored CD4+ T cell proliferation, thus 
suggesting a preferential role for arginase-1 in our model.  
It has been suggested that the suppressive activity of MDSCs is dependent on 
the immunomodulatory cytokine IL-10 (17) although this finding is not 
universally supported (33). However, signalling through the IL-10-receptor was 
found to be required to establish the suppressive phenotype in MDSCs (33), 
which supports our findings that although addition of a blocking anti-IL-10R 
antibody did not restore CD4+ T cell proliferation, tolerisation of IL-10-deficient 
animals showed a change in the phenotype of PMN-MDSCs compared to IL-10-
sufficient mice.  
In addition to these soluble factors, the cell surface molecules PD-L1 and 
Galectin-9 have been suggested to mediate the T cell suppressive effect (6, 
18). In our study the blockade of either cell surface receptor separately during in 
vitro co-culture using neutralising antibodies did not restore T cell proliferation 
whereas the co-blockade of both molecules together led to the abrogation of 
suppression, indicating a synergistic effect. 
The frequency of PMN-MDSC in mice with induced EAE was significantly higher 
in many of the organs examined than in mice that had been protected by EDI. 
This raises the question why animals are not protected from disease even 
though these potentially immunosuppressive PMN-MDSCs arise. Our findings 
hint at the possibility that phenotypic differences between those PMN-MDSCs 
that develop after EAE development and those that arise after tolerisation 
contribute to their functional dichotomy. Compared to the PMN-MDSCs of mice 
with EAE, we detected a higher expression of Galectin-9 and PD-L1 on PMN-
MDSCs in the spleen and lymph nodes with an increase of CD40 and a 
decrease of CD80 in the CNS compartment of tolerised animals. The exact role 
of CD40 in MDSC-mediated suppression remains unclear but Pan et al. showed 
that CD40 expressed on MDSCs is essential for their suppressive function and 
T reg cell induction (19). This is supported by our in vitro findings, where 
blockade of CD40 abrogated PMN-MDSC-suppression and restored CD4+ T 
cell proliferation. 
In recent years, the expression of CD80 on MDSCs has been associated with 
immune suppression (20), which corroborates our findings that the addition of 
anti-CD80 to our in vitro co-cultures led to abrogation of MDSC-mediated 
inhibition of CD4+ T cell proliferation. This, however, is in direct contrast to our 
hypothesis that peptide treatment promotes a more suppressive PMN-MDSC 
phenotype in the CNS, as we found a reduced expression of CD80 on PMN-
MDSCs in the CNS of tolerised animals. The effect of CD80 expression on the 
function of PMN-MDSCs remains unclear however, as it was shown previously 
that, in a rat model of kidney allograft tolerance, blood-derived CD80-positive 
MDSCs have the same suppressive capacity as their CD80-negative 
counterparts (34). Overall, it is unclear how important the phenotype of PMN-
MDSCs in the CNS is for the prevention of EAE as the maintenance of 
tolerance and prevention of disease development may very well be controlled in 
the periphery rather than the CNS. After all, removal of the spleen prevented 
successful tolerance induction and hence protection from disease. This was 
also shown previously in a model of experimental autoimmune uveoretinitis 
(EAU) where splenectomy likewise abrogated the induction of tolerance (35). 
PD-L1 expression on PMN-MDSCs was increased only in the spleen and no 
other organs of tolerised animals. PD-L1+ PMN-MDSCs could potentially 
interact with PD-1-expressing CD4+ T cells in the spleen (5). Tumour-infiltrating 
MDSCs from tumour-bearing mice have previously been shown to express high 
levels of PD-L1 and to be able to suppress the proliferation of CD8+ T cells (18). 
MDSC-mediated T cell suppression may thus be mediated by the PD-L1-PD-1 
axis and that this interaction is likely take to place in the spleen. Another 
important negative regulator of T cell activity, TIM-3, was significantly 
upregulated on CD4+ T cells in the spleen of tolerised animals that were 
protected from EAE in our study (5). An earlier study described a potential role 
for the Tim-3/Galectin-9 pathway in MDSC proliferation (6). 
Our results suggest that MDSC-mediated plasticity of conventional T cells in the 
spleen, and not just the differentiation of Treg cells might, at least in part, be 
responsible for the protective effect of EDI. After all, our splenectomy 
experiments showed that animals without a spleen receiving EDI were still more 
susceptible to EAE than mice that retained their spleen. Our findings are 
supported by a study where splenectomy prior to tolerance induction to OVA did 
not affect the number of CD4+ Treg cells yet the establishment of skin tolerance 
could not be achieved (36). Previous work implied that T cells need to migrate 
through the spleen to become encephalitogenic and cause disease, in a 
process known as T cell licensing (37). One could speculate that PMN-MDSCs 
in the spleen may prevent T cell licensing, although this will require further 
investigation. 
Our work further provides evidence for a direct effect of PMN-MDSCs on the 
encephalogenicity of Th1 cells, as T cells cultured in the presence of PMN-
MDSCs are less potent inducers of EAE. Animals developed less severe EAE 
symptoms and recovered faster from disease compared to animals that 
received Th1 cells polarised under normal conditions. 
Overall, we demonstrate here that PMN-MDSCs play an important role in 
tolerance induction during antigen-specific immunotherapy of autoimmune 
disease. Their differentiation should therefore be a prime target of treatment 
and may be an indicator of successful therapy. 
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Figure legends 
Figure 1. Increase in M-MDSCs and PMN-MDSCs during EDI. Shown are 
representative FACS plots from different organs from PBS-treated and MBPAc1-
9(4Y)- treated TG4 animals, gated on single, viable CD11b+ cells. Organs from 
PBS controls (A) or MBPAc1-9(4Y)-animals (B) were isolated and stained with a 
panel of antibodies and two subpopulations of MDSCs were identified by flow 
cytometry. Representative of three individual experiments. C) Shown is the 
frequency of PMN-MDSCs during EDI after the 3rd and 5th dose of MBPAc1-9(4Y) 
in various organs compared to control mice receiving one dose of PBS. The 
gating strategy excluded dead cells and doublets. Horizontal lines indicate 
mean. After checking for normality using the Shapiro-Wilk test the Kruskal-
Wallis test followed by Dunn’s multiple comparison test for data that were not 
normally distributed was used (* = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = 
p ≤ 0.0001). In the spleen, ILNs, BLNs and lung each dot represents one 
individual mouse. In the liver in some cases cells from two animals were 
combined due to low cell numbers while in the CNS compartment each dot 
represents two individuals. N=6, from two independent experiments. 
Figure 2. Phenotypic analysis of PMN-MDSCs after dose escalation 
immunotherapy. A) Representative flow cytometry plot of splenic PMN-MDSCs 
from MBPAc1-9(4Y)-  (black line) and PBS control-treated (filled grey line) 
animals after gating on viable CD11b+ Ly6G+ cells and comparison of Galectin-
9, PD-L1, CD40, CD80 and CD86 expression shown as histogram overlays. 
Dotted line indicates negative staining control. B) Bar graph shows mean + 
SEM. After checking for normality using the Shapiro-Wilk test either ANOVA 
followed by Sidak’s multiple comparison test was performed for normally 
distributed data or the Kruskal-Wallis test followed by Dunn’s multiple 
comparison test for data that were not normally distributed (* = p ≤ 0.05, ** = p ≤ 
0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001). Data on the left of the vertical line had 
a normal distribution. In the spleen, ILNs, BLNs and lung each bar graph 
represents six individuals. In the liver in some cases cells from two animals 
were combined due to low cell numbers (n = 4) while in the CNS compartment 
each measurement contained cells from two animals. Kruskal-Wallis test 
followed by Dunn’s multiple comparison test was applied to CD40, CD80 and 
CD86 data. N=6, from two independent experiments. 
Figure 3. Splenic PMN-MDSCs suppress the proliferation of CD4+ T cells in an 
antigen-specific manner. PMN-MDSCs were co-cultured for four days together 
with naïve (Tnaiv) and antigen-experienced T cells (Tag) labelled with cell 
proliferation dye at a ratio of 1:3 with their cognate peptide and CD11c+ cells 
used as APCs. Gated on single, viable CD4+ T cells. A) Proliferation of Tnaiv 
and Tag CD4+ T cells after culture with or without PMN-MDSCs (n=5). Box 
shows 25th to 75th percentiles. The horizontal line is plotted at the median. 
Whiskers show Min to Max. Mean is shown as a '+'. B) Foxp3 expression in 
CD4+ Tnaiv and CD4+ Tag after culture with or without PMN-MDSC’s (n=5). Box 
shows 25th to 75th percentiles. The horizontal line is plotted at the median. 
Whiskers show Min to Max. '+' indicates mean. After checking for normality 
using the Shapiro-Wilk test ANOVA followed by Sidak’s multiple comparison 
test was performed for normally distributed data (* = p ≤ 0.05, ** = p ≤ 0.01, *** 
= p ≤ 0.001, **** = p ≤ 0.0001). 
Figure 4. Splenic PMN-MDSCs suppress CD4+ T cell proliferation induced by 
plate-bound anti-CD3 and anti-CD28 in a cell-contact dependent manner. Naïve 
(Tnaiv) (A) or antigen-experienced CD4+ T cells (Tag) (B) labelled with cell 
proliferation dye, were cultured with PMN-MDSCs from either tolerised (n=6) or 
PBS-treated mice (n=3) on an anti-CD3+antiCD28-coated plate at a ratio of 1:1. 
C) Splenic, FACS-sorted PMN-MDSC from tolerised mice and CD4+ Tag cells 
were cultured together at a ratio of 1:1 in on anti-CD3+anti-CD28-coated plate, 
separated by a membrane (n=3). Gated on single, viable CD4+ T cells. Box 
shows 25th to 75th percentiles. The horizontal line is plotted at the median. 
Whiskers show Min to Max. '+' indicates mean. Kruskal-Wallis test followed by 
Dunn’s multiple comparison test was performed for data that were not normally 
distributed (* = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001). 
Figure 5. Determination of the mechanism of PMN-MDSCs mediated CD4+ T 
cell suppression in vitro. Splenic, FACS-sorted PMN-MDSC from tolerised mice 
and CD4+ Tag cells were cultured together at a ratio of 1:1 on an anti-CD3+anti-
CD28-coated plate. A) Antibodies to Galectin-9, PD-L1, CD40, CD80, CD86 
and IL-10R (10 g/ml) or B) chemical inhibitors of iNOS (L-NMMA) or arginase-
1 (BEC) (both at 500 M) were added for the duration of the culture (n = 3 
each). Gated on single, viable CD4+ T cells. Box shows 25th to 75th percentiles. 
The horizontal line is plotted at the median. Whiskers show Min to Max. '+' 
indicates mean. Kruskal-Wallis test followed by Dunn’s multiple comparison test 
was performed (* = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001). 
Figure 6. Frequencies and phenotype of PMN-MDSCs in peripheral organs in 
diseased versus tolerised mice. Tg4 mice were treated with PBS or MBPAc1-
9(4Y)-EDI before the induction of EAE. Animals were analysed at the peak of 
disease when mice treated with PBS showed complete hind limb paralysis 
(grade 3) and EDI-treated animals showed no sign of disease. A) Shown are 
single, viable CD11b+ Ly6G+ cells. Horizontal lines indicate mean. After 
checking for normality using the Shapiro-Wilk test the unpaired t test was 
performed for normally distributed data (* = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 
0.001, **** = p ≤ 0.0001). Each dot represents one individual, n=7-11. Pooled 
data from three independent experiments. B) Single, viable PMN-MDSCs were 
analysed for the expression of CD40, CD80, Galectin-9 and PD-L1. Horizontal 
lines indicate mean. After checking for normality using the Shapiro-Wilk test 
either unpaired t test was performed for normally distributed data or the Mann-
Whitney U test for data that were not normally distributed (* = p ≤ 0.05, ** = p ≤ 
0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001). Each dot represents one individual, 
n=7-11. Pooled data from three independent experiments. Unpaired t test was 
applied to CNS data. Unpaired t test was applied to Galectin-9 BLN data and 
PD-L1 data whereas the Mann-Whitney U test was applied to spleen Galectin-9 
data. 
Figure 7. Splenectomy impairs the increase in the number of PMN-MDSCs post 
EDI and prevents tolerance induction. Tg4 mice underwent either a sham 
operation or splenectomy 14 days before EDI to induce tolerance or PBS only 
as a control. Thereafter, ILNs, BLNs, lungs and liver were removed and 
analysed by flow cytometry (each dot represents an animal), gated on single, 
viable cells. Horizontal lines in A and B indicate mean. After checking for 
normality using the Shapiro-Wilk test either ANOVA followed by Sidak’s multiple 
comparison test was performed for normally distributed data or the Kruskal-
Wallis test followed by Dunn’s multiple comparison test for data that were not 
normally distributed (* = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 
0.0001). A) Percentage of CD11b+ Ly6G+ PMN-MDSCs in the ILN, BLN, lung 
and liver in splenectomised or sham-operated mice that have either been 
tolerised with MBPAc1-9(4Y) or received control treatment with PBS only. ANOVA 
followed by Sidak’s multiple comparison test was applied to ILN (n=6-7, pooled 
data from 2 independent experiments) and BLN data (n=6-7, pooled data from 2 
independent experiments). Kruskal-Wallis test followed by Dunn’s multiple 
comparison test was applied to lung and liver data (n=3-4, one experiment). B) 
Absolute numbers of CD11b+ Ly6G+ PMN-MDSCs in the ILN, BLN, lung and 
liver in splenectomised or sham-operated mice that have either been tolerised 
with MBPAc1-9(4Y) or received control treatment with PBS only.  ANOVA 
followed by Sidak’s multiple comparison test was applied to ILN (n=6-7, pooled 
data from 2 independent experiments) and BLN data (n=6 -7, pooled data from 
two independent experiments). Kruskal-Wallis test followed by Dunn’s multiple 
comparison test was applied to lung and liver data (n=3-4, one experiment). C) 
Tg4 mice underwent either sham operation or splenectomy 14 days before EDI 
to induce tolerance or were treated with PBS as a control. Subsequently, EAE 
was induced and animals were monitored daily for 20 days for signs of disease. 
Line graph shows disease scores over time (mean+SEM). Bar graph shows 
area under the curve (AUC, mean+SEM). One-way ANOVA with Tukey’s 
multiple comparison post hoc test p ≤ 0.05, n=9-12 for each group, pooled data 
from three independent experiments, mean+SEM). 
Figure 8. Signalling through the IL-10 receptor is required for PMN-MDSCs 
accumulation. Tg4IL-10-/- mice or wild-type Tg4 mice were either treated with 
PBS as a control or MBPAc1-9(4Y) according to the EDI protocol until the 3rd 
dose before isolating the spleen and lymph nodes to define quantity of PMN-
MDSCs. Horizontal lines indicate mean. Each dot represents one individual, 
n=4-6, pooled data from three independent experiments. Kruskal-Wallis test 
followed by Dunn’s multiple comparison test was performed for data that were 
not normally distributed (* = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 
0.0001). A) Percentages of CD11b+ Ly6G+ PMN-MDSCs in spleen and lymph 
nodes of PBS or MBPAc1-9(4Y)-treated wild-type Tg4 and Tg4IL-10-/- mice, gated 
on single, viable cells. B) Absolute numbers of CD11b+ Ly6G+ PMN-MDSCs in 
spleen and lymph nodes of PBS or MBPAc1-9(4Y)-treated wild-type Tg4 and 
Tg4IL-10-/- mice. Definition of the phenotype of PMN-MDSCs, gated on single, 
viable CD11b+ Ly6G+ PMN-MDSCs. N=4-6, pooled data from two to three 
independent experiments. Kruskal-Wallis test followed by Dunn’s multiple 
comparison test was performed for data that were not normally distributed (* = p 
≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001). Bar graph shows mean 
+ SEM. C) CD80 expression on CD11b+ Ly6G+ PMN-MDSCs in spleen and 
lymph nodes of PBS or MBPAc1-9(4Y)-treated wild-type Tg4 and Tg4IL-10-/- 
mice. D) CD86 expression on CD11b+ Ly6G+ PMN-MDSCs in spleen and lymph 
nodes of PBS or MBPAc1-9(4Y)-treated wild-type Tg4 and Tg4IL-10-/- mice. 
Figure 9. Adoptive transfer of PMN-MDSCs reduces CD4+ T cell proliferation 
after antigen prime ex vivo. Tg4 mice received either a cell transfer of 1.5x106 
FACS sorted PMN-MDSC i.p. or no transfer three days before priming with 
MBPAc1-9(4K) peptide in CFA at the base of the tail. Ten days post-prime, spleen 
and ILNs were harvested and a 3[H]-Thymidine assay set up. A) Proliferative 
response of whole cell isolates from the spleen and ILN, after restimulation in 
vitro with titrated doses of MBPAc1-9(4K) (n = 6 - 8, pooled data from two 
independent experiments). Line graph shows mean ± SEM. After checking for 
normality using the Shapiro-Wilk test the unpaired t test was performed for 
normally distributed data (* = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 
0.0001). B) Proliferative response of magnetically isolated CD4+ T cells from the 
spleen and ILN, after restimulation in vitro with titrated doses of MBPAc1-9(4K) in 
the presence of irradiated APCs (n = 3). Mann-Whitney U test (* = p ≤ 0.05, ** = 
p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001) C) ICCS of isolated single, viable 
CD4+ T cells from spleen and lymph nodes. Each dot represents one individual 
(n=3). Horizontal lines indicate mean. (Mann-Whitney U test). 
Figure 10. PMN-MDSCs limit the encephalogenicity of Th1 cells. Tg4 mice 
received an adoptive transfer of 5x106 Th1 cells that were differentiated in vitro in 
the presence (PMN-MDSC-Th1) or absence of PMN-MDSCs (Th1) (n=5 per 
group). Line graph and bar graph show mean + SEM. Mann-Whitney U test was 
performed for comparison of mean EAE score of individual days. Unpaired t-test 
with Welch’s correction was used for the comparison of AUCs. (* = p ≤ 0.05, ** 
= p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001). 
  
Table 1. PMN-MDSCs limit the encephalogenicity of Th1 cells. Tg4 mice 
received an adoptive transfer of 5x106 Th1 cells that were differentiated in vitro 
in the presence (PMN-MDSC-Th1) or absence of PMN-MDSCs (n=5 per group). 
* Day of onset is the first day mice showed signs of EAE after cell transfer. † 
Incidence is the number of cases of EAE/number of mice immunized for each 
group.  
treatment day of 
onset* 
mean ± 
SEM 
incidence† maximum 
score 
mean ± SEM 
area under 
the curve 
mean ± 
SEM 
polarised under normal Th1 conditions  
Th1 6.8 ± 0.86 5/5 3 ± 0.54 32.6 ± 0.92 
Th1 cells polarised under PMN-MDSCs influence 
PMN-MDSC-Th1 5.8 ± 0.36 5/5 2 ± 0 15.2 ± 0.27 
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